Brigitte Kolb

Reims, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

Journal: Blood
Published: November 01, 2021

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.

Journal: Leukemia
Published: May 18, 2021

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.

Journal: Haematologica
Published: June 09, 2020

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

Journal: Lancet (London, England)
Published: March 15, 2019

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 06, 2018

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Journal: Leukemia
Published: October 05, 2018

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Journal: Blood
Published: June 20, 2018

Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial.

Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial.

Journal: JAMA
Published: December 07, 2017

Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.

Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.

Journal: Leukemia & lymphoma
Published: July 13, 2017

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

Journal: Annals of hematology
Published: January 03, 2017

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

Journal: Blood
Published: January 16, 2016

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 11, 2015
Showing 1-12 of 25

Last Updated: 09/26/2026